医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Vitruvias Therapeutics and Sunny Pharmtech Form Partnership to Co-Develop Several High Value Generic Drugs

2015年04月14日 PM11:33
このエントリーをはてなブックマークに追加


 

MONTGOMERY, Ala. & TAIPEI, Taiwan

Sunny Pharmtech Inc., a Taiwan-based API and finished-dose drug development company, and Vitruvias Therapeutics LLC, a generic drug development company, announced today that they have formed a strategic partnership to co-develop a varied portfolio of generic drugs.

The agreement will leverage the research, development, and distribution capabilities of each company to quickly and efficiently develop and commercialize generic products in markets that currently exceed $400 mil. Each company will have a 50% stake in product portfolio, and the first ANDA will be tentatively filed in the fourth quarter of 2015.

“We are fortunate to have the opportunity to partner with a company as technologically sophisticated as Sunny Pharmtech given their expertise in the development of API and finished dose formulations,” said Carl Whatley, General Manager of Vitruvias. “Sunny Pharmtech provides us with the know-how to develop difficult products in under-served U.S. markets and we look forward to addressing the needs of those markets as soon as we possibly can.”

Dr. Yon-Lian Wu, Sunny Pharmtech’s CEO and Chairperson added, “I am delighted to announce this strategic partnership between Sunny Pharmtech and Vitruvias. It will leverage both companies’ respective strengths to meet the needs of patients for high quality and cost-effective generic pharmaceuticals. For Sunny Pharmtech, this agreement will enhance our efforts to establish a world-class platform to support our efforts in the generic pharmaceutical products area. By combining our respective capabilities in this joint effort, Sunny Pharmtech and Vitruvias are creating a global business model and a robust base in the generic pharmaceuticals market.”

About Sunny Pharmtech Inc.

Sunny Pharmtech Inc. is an emerging specialty pharmaceutical company based in Taiwan and was founded in 2004 with a focus on the development of technically difficult products. In 2014, the capability of developing and producing active pharmaceutical ingredients was added. The resulting organization is now fully-integrated, doing research, development, and manufacturing on both API and finished-dose products which includes orals, liquids, semi-solids, and parenterals.

About Vitruvias Therapeutics LLC

Vitruvias is an emerging specialty pharmaceutical company which develops, manufactures, and markets generic prescription products for the U.S. and Canadian markets. Founded in 2013 by industry veterans Carl Whatley and Bryce Harvey, the privately-held company specializes in generic semi-solid and parenteral products. The current focus of the company is on the development of selective, high-value generic products with their first approval expected in 2016. www.vitruvias.com

CONTACT

Vitruvias Therapeutics LLC
Carl Whatley, 334-647-1948
carl@vitruvias.com
or
Sunny
Pharmtech Inc.
Newman Pui, +886 22664-9600
newman.pui@sunnypharmtech.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • フェリングが微生物叢ベースのライブバイオ治療薬RBX2660に関する米国FDA諮問委員会会議の開催を発表
  • 辉凌宣布美国FDA咨询委员会就公司基于微生物群的在研活体生物疗法RBX2660召开会议
  • Taiwan Excellence Pavilion Showcasing at The AACC Expo (American Association for Clinical Chemistry) for the First Time
  • Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-Guideline Genomic Factors
  • 2022 International Symposium on Human Identification (ISHI) Keynote DeNeen L. Brown Outlines Search for Victims of 1921 Tulsa Race Massacre